- Home
- GLSI vs SHMD Comparison
GLSI vs SHMD Comparison
Compare GLSI & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- SHMD
- Stock Information
- Founded
- GLSI 2006
- SHMD 1864
- Country
- GLSI United States
- SHMD Germany
- Employees
- GLSI N/A
- SHMD N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- SHMD
- Sector
- GLSI Health Care
- SHMD
- Exchange
- GLSI Nasdaq
- SHMD Nasdaq
- Market Cap
- GLSI 143.4M
- SHMD 144.3M
- IPO Year
- GLSI 2020
- SHMD N/A
- Fundamental
- Price
- GLSI $12.87
- SHMD $2.47
- Analyst Decision
- GLSI Strong Buy
- SHMD
- Analyst Count
- GLSI 1
- SHMD 0
- Target Price
- GLSI $38.00
- SHMD N/A
- AVG Volume (30 Days)
- GLSI 43.0K
- SHMD 46.6K
- Earning Date
- GLSI 11-14-2024
- SHMD 02-25-2025
- Dividend Yield
- GLSI N/A
- SHMD N/A
- EPS Growth
- GLSI N/A
- SHMD 1309.32
- EPS
- GLSI N/A
- SHMD 1.07
- Revenue
- GLSI N/A
- SHMD $99,752,404.00
- Revenue This Year
- GLSI N/A
- SHMD N/A
- Revenue Next Year
- GLSI N/A
- SHMD N/A
- P/E Ratio
- GLSI N/A
- SHMD $2.30
- Revenue Growth
- GLSI N/A
- SHMD N/A
- 52 Week Low
- GLSI $8.00
- SHMD $1.98
- 52 Week High
- GLSI $21.44
- SHMD $6.13
- Technical
- Relative Strength Index (RSI)
- GLSI 51.89
- SHMD N/A
- Support Level
- GLSI $11.50
- SHMD N/A
- Resistance Level
- GLSI $12.84
- SHMD N/A
- Average True Range (ATR)
- GLSI 0.90
- SHMD 0.00
- MACD
- GLSI 0.09
- SHMD 0.00
- Stochastic Oscillator
- GLSI 59.49
- SHMD 0.00
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).